'The BD Veritor At-Home COVID-19 Test enables people to test from home, without a proctor, while ensuring verifiable results because test results can only be read using a smartphone,' said
How It Works
The BD Veritor At-Home COVID-19 Test uses a mobile app to interpret and provide a digital display of testing results in 15 minutes. The test is one of the only at-home tests to fully automate reporting of results to federal and state public health agencies and provides a streamlined experience for optional reporting to businesses and schools. The addition of ReturnSafe gives those organizations the insights and tools to manage their testing programs at scale. By using the BD Veritor At-Home COVID-19 Test with ReturnSafe, employers can effectively collect test results, track who has completed testing requirements on time, quickly identify positive cases to act, manage isolation and quarantine workflows, as well as collect data for compliance reporting.
By using the BD Veritor At-Home COVID-19 Test, employees can upload their test results from the comfort of their own home via technology that digitally reads and verifies the result and imports it directly into the ReturnSafe Command Center. This removes the need for proctors or manually reviewing tests uploaded into the ReturnSafe system.
An End-to-End Solution for Businesses
Superhuman, a startup building the fastest email experience in the world, is working with ReturnSafe to use the combined solution of its platform and the BD Veritor At-Home COVID-19 Test to manage their enterprise's employee testing status.
'Solving testing and vaccine tracking for our organization has been made possible through our partnership with ReturnSafe and BD,' said
The test is available for businesses by visiting, BDVeritorAtHome.com, clicking on 'Buying Options' and selecting 'Contact Our Sales Team.' The BD Veritor At-Home COVID-19 Test is also currently available for consumers online at Amazon.com, CVS.com and
About the BD Veritor At-Home COVID-19 Test
The BD Veritor At-Home COVID-19 Test has not been FDA cleared or approved; but has been authorized by FDA under Emergency Use Authorization (EUA). This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of IVDs for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. (*) 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.
About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 75,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and Twitter @BDandCo.
About ReturnSafe
ReturnSafe is a comprehensive software solution for COVID-19 health safety that is helping businesses, universities, healthcare facilities, sports teams and organizations of all sizes reopen and stay open. The all-in-one platform provides vaccination status tracking, test program management, case management and policy-based building access controls enabling a safe return to work at scale. ReturnSafe customers minimize business disruption, comply with regulations, gain higher HR productivity and have employees participating in their health safety in the workplace. ReturnSafe is based in
Contact:
Media
BD Public Relations
T: 908-500-0555
E: brooke.houston@bd.com
Investors
SVP
Head of Investor Relations
T: 201.847.5743
E: francesca.demartino@bd.com
(C) 2022 Electronic News Publishing, source